Nitrogen In Y Moiety Patents (Class 514/540)
-
Publication number: 20040054001Abstract: The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives for preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB.Type: ApplicationFiled: July 10, 2003Publication date: March 18, 2004Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel, Peter Petzelbauer
-
Publication number: 20040043943Abstract: A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone, and for other therapy.Type: ApplicationFiled: August 20, 2003Publication date: March 4, 2004Inventors: George V. Guittard, Francisco Jao, Susan M. Marks, David J. Kidney, Fernando E. Gumucio
-
Publication number: 20040044075Abstract: Disclosed herein is a compound represented by Structural Formula (I): 1Type: ApplicationFiled: May 29, 2003Publication date: March 4, 2004Applicant: Genzyme CorporationInventors: Mark M. Staveski, Scott F. Sneddon
-
Publication number: 20040034105Abstract: The invention relates to the use of 1-phenyl-3-dimethylaminopropane compounds for treating increased urinary urgency or urinary incontinence, as well as to the production of corresponding medicaments.Type: ApplicationFiled: May 30, 2003Publication date: February 19, 2004Applicant: Gruenenthal GmbHInventors: Thomas Christoph, Elmar Friderichs
-
Publication number: 20040013741Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.Type: ApplicationFiled: July 15, 2002Publication date: January 22, 2004Inventors: Gerard M. Meisel, Arthur A. Ciociola
-
Publication number: 20040009234Abstract: The invention relates to compositions and methods for treating and/or preventing lower gastrointestinal (GI) disorders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with such disorders.Type: ApplicationFiled: July 10, 2002Publication date: January 15, 2004Inventors: Gerard M. Meisel, Arthur A. Ciociola
-
Publication number: 20040010038Abstract: The subject invention provides derivatives of propargylamino indan (PAI) and propargylamino tetralin that selectively inhibit monoamine oxidase (MAO) in the brain, having the structure: 1Type: ApplicationFiled: February 27, 2003Publication date: January 15, 2004Inventors: Eran Blaugrund, Yaacov Herzig, Jeffrey Sterling
-
Publication number: 20040002539Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1Type: ApplicationFiled: April 22, 2003Publication date: January 1, 2004Applicant: 3-Dimensional Pharmaceuticals, Inc.Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L. Fedde, Carl R. Illig, Thomas P. Markotan
-
Publication number: 20030235631Abstract: The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.Type: ApplicationFiled: March 12, 2003Publication date: December 25, 2003Applicant: Pfizer Inc.Inventors: Susan B. Sobolov-Jaynes, Christopher J. Schmidt
-
Publication number: 20030220399Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.Type: ApplicationFiled: March 4, 2003Publication date: November 27, 2003Applicants: Metabolex, Inc., DiaTex, Inc.Inventors: Kenneth L. Luskey, Jian Luo
-
Publication number: 20030203037Abstract: The invention relates to parenteral dosage forms of administration that comprise a suspension of the salt of the active substances tramadol and diclofenac.Type: ApplicationFiled: May 21, 2003Publication date: October 30, 2003Inventors: Johannes Bartholomaus, Heinrich Kugelmann
-
Publication number: 20030199580Abstract: This invention provides a process for the preparation of a benzimidazole derivative (I) or a pharmaceutically acceptable salt thereof, 1Type: ApplicationFiled: October 16, 2002Publication date: October 23, 2003Applicant: SANKYO COMPANY, LIMITEDInventors: Naoyuki Kishi, Yoshitaka Nakamura, Narumi Abe, Toyonori Takebayashi
-
Publication number: 20030191183Abstract: This invention provides to a method for enhancement of systemic delivery of oxybutynin by administration via the nasal route, and methods of treatment comprising intranasal administration of oxybutynin. The present invention further provides pharmaceutical compositions comprising oxybutynin and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 31, 2003Publication date: October 9, 2003Inventors: Amanda J. Sherratt, Abdulghani A. Houdi
-
Publication number: 20030187034Abstract: The present invention relates to a composition, comprisingType: ApplicationFiled: May 23, 2003Publication date: October 2, 2003Inventors: Joachim Bunger, Hansjurgen Driller, Michael Schwarz, Wolfgang Wohlrab
-
Publication number: 20030185882Abstract: A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided.Type: ApplicationFiled: November 6, 2001Publication date: October 2, 2003Inventors: Juan A. Vergez, Marcelo A. Ricci
-
Publication number: 20030181517Abstract: This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula: 1Type: ApplicationFiled: March 25, 2003Publication date: September 25, 2003Applicant: WyethInventors: Richard L. Rudolph, Albert T. Derivan, Eric A. Muth, G. Virginia Upton
-
Patent number: 6610739Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition is Additional alternative embodiments are R or R″ that are therapeutic moieties.Type: GrantFiled: August 21, 2002Date of Patent: August 26, 2003Assignee: Nobex CorporationInventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs
-
Publication number: 20030158152Abstract: The present invention refers to synthetic protease inhibitors having an axis of symmetry C2 or pseudo-C2 characterised by possessing, in the central portion: (1) preferably, a dihydroxyethylene function, which is isosteric with a peptidic bond; (2) a peptidemimetic bridge between the two nitrogens of the main chain and (3) radicals capable of mimetising amino acids. These new protease inhibitors are a base for the preparation of anti-viral formulations capable of inhibiting HIV virus proliferation.Type: ApplicationFiled: November 15, 2002Publication date: August 21, 2003Inventors: Emerson Poley Pecanha, Luciana J.O. Figueiredo, Vera Bongertz, Octavio Augusto Ceva Antunes, Amilcar Tanuri, Rodrigo de Moraes Brindeiro
-
Publication number: 20030157156Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to transdermally administered oxybutynin. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the drug through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Formulations, drug delivery systems and methods of treatment are provided as well.Type: ApplicationFiled: February 20, 2003Publication date: August 21, 2003Inventors: Tsung-Min Hsu, Eric C. Luo
-
Publication number: 20030149084Abstract: This invention provides a method of inhibiting proliferation of tumor cells in a subject by administering to the subject an effective amount of ester and thioester compounds containing an N-formyl hydroxylamine group.Type: ApplicationFiled: December 10, 2002Publication date: August 7, 2003Inventors: Andrew Paul Ayscough, Lisa Marie Pratt, Alan Hastings Drummond
-
Publication number: 20030147926Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.Type: ApplicationFiled: November 1, 2002Publication date: August 7, 2003Applicant: Watson Pharmaceuticals, Inc.Inventors: Charles D. Ebert, Steven W. Sanders
-
Publication number: 20030129245Abstract: The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.Type: ApplicationFiled: November 18, 2002Publication date: July 10, 2003Inventor: Eva Trofast
-
Publication number: 20030124177Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: ApplicationFiled: November 1, 2002Publication date: July 3, 2003Applicant: Watson Pharmaceuticals, Inc.Inventors: Charles D. Ebert, Steven W. Sanders
-
Patent number: 6576780Abstract: The current invention discloses hydroxyamidino derivatives useful as nitric oxide synthase inhibitors.Type: GrantFiled: October 13, 2000Date of Patent: June 10, 2003Assignee: GD Searle & CompanyInventors: Rolando E. Gapud, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Barnett S. Pitzele, Suzanne S. Metz, R. Keith Webber, Foe S. Tjoeng, Robert E. Manning, Mihaly V. Toth
-
Publication number: 20030105148Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.Type: ApplicationFiled: August 9, 2002Publication date: June 5, 2003Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
-
Publication number: 20030100598Abstract: New esters derived from substituted phenyl-cyclohexyl compounds, which are derived from Tramadol, process for obtaining them and their use for preparing a drug with analgesic properties. These new compounds of general formula (I) have a higher analgesic activity, a lower toxicity and a longer effective time period than Tramadol.Type: ApplicationFiled: June 27, 2002Publication date: May 29, 2003Inventors: Marisabel Mourelle Mancini, Elisabet De Ramon Amat, Juan Huguet Clotet
-
Publication number: 20030100606Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same.Type: ApplicationFiled: October 29, 2002Publication date: May 29, 2003Inventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs-Sauthier
-
Publication number: 20030078297Abstract: Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.Type: ApplicationFiled: July 15, 2002Publication date: April 24, 2003Inventors: L. David Waterbury, Allan L. Wilcox, John M. Carney, Farah Mavandadi, Albert Danielzadeh
-
Publication number: 20030065016Abstract: Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.Type: ApplicationFiled: April 11, 2002Publication date: April 3, 2003Inventors: Ru Chih C. Huang, Jonathan D. Heller, Jih Ru Hwu, Ko Yung King
-
Patent number: 6538152Abstract: The present invention provides novel phenoxyacetic acid derivatives represented by the general formula: wherein R1 represents a hydroxy group, a lower alkoxy group, an aralkoxy group, an amino group, or a mono or di(lower alkyl)amino group; one of R2 and R3 is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, while the other is a hydrogen atom; R4 represents a halogen atom, a lower alkyl group, a halo(lower alkyl) group, a hydroxy group, a lower alkoxy group, an aralkoxy group, a cyano group, a nitro group, an amino group, a mono or di(lower alkyl)amino group, a carbamoyl group, a mono or di(lower alkyl)carbamoyl group or a group represented by the general formula: —NHCOR5 (wherein R5 represents a hydrogen atom or a lower alkyl group); the carbon atom marked with (R) represents a carbon atom in R configuration; and the carbon atom marked with (S) represents a carbon atom in S configuration, and pharmaceutically acceptable salts thereof, which have excellenType: GrantFiled: January 3, 2001Date of Patent: March 25, 2003Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Nobuyuki Tanaka, Tetsuro Tamai, Harunobu Mukaiyama, Akihito Hirabayashi, Hideyuki Muranaka, Masaaki Sato, Masuo Akahane
-
Publication number: 20020165276Abstract: The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat inflammatory somatic pain as well as chronic pain.Type: ApplicationFiled: November 7, 2001Publication date: November 7, 2002Inventors: Gilles Brunelle, Agnes Grouhel, Jacques Hamon, Francois Roman
-
Publication number: 20020160045Abstract: A dosage form, a therapeutic composition, and the use thereof is disclosed for administering a therapeutic agent accompanied by a pharmaceutically acceptable means administered for an indicated therapy.Type: ApplicationFiled: June 4, 2002Publication date: October 31, 2002Inventors: Michael A. Desjardin, Paul M. Hwang, Halle Treanor
-
Publication number: 20020161040Abstract: Use of at least one aminophenol derivative of formula (I) below: 1Type: ApplicationFiled: April 19, 2002Publication date: October 31, 2002Applicant: L'OREALInventors: Michel Philippe, Remy Tuloup, Christian Blaise
-
Patent number: 6469063Abstract: The present invention is directed to a method of treating inflammation comprising administering to a subject in need thereof an amount of a caffeic acid derivative sufficient to inhibit the transcription of COX-2. In a preferred embodiment the caffeic acid derivative is a cyanocinnamate, most preferably cinnamamyl-3,4-dihydroxy-&agr;-cyanocinnamate.Type: GrantFiled: November 17, 2000Date of Patent: October 22, 2002Assignee: City of HopeInventors: David Bleich, Songyuan Chen, Xiao Han
-
Publication number: 20020147236Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.Type: ApplicationFiled: March 15, 2002Publication date: October 10, 2002Inventors: Steven W. Sanders, Charles D. Ebert
-
Patent number: 6458837Abstract: The invention discloses stable diesters of chelating agents of divalent metal ions, processes for their preparation and pharmaceutical compositions thereof. Most preferred compounds according to the present invention are stable lipophilic diesters comprising a covalent conjugate of a BAPTA and a pharmaceutically acceptable alcohol. The diesters are useful in a method for treating a condition or disease related to an excess of divalent metal ions, and in particular for the treatment of a condition or disease related to elevated levels of intracellular calcium ions, such as in brain or cardiac ischemia, stroke, epilepsy, Alzheimer's disease or cardiac arrhythmia and in open heart surgery.Type: GrantFiled: March 27, 2000Date of Patent: October 1, 2002Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Patent number: 6451786Abstract: Compounds defined by the following general structure are disclosed: These compounds display pharmacological activities, including inhibition of tyrosine kinase activity and enhancement of the function and/or survival of trophic factor responsive cells, e.g., cholinergic neurons.Type: GrantFiled: February 15, 2000Date of Patent: September 17, 2002Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.Inventors: Robert L. Hudkins, Diane E. Gingrich
-
Publication number: 20020098175Abstract: Food composition in the form of a flour comprising at least 50% of protein, less than 15% of carbohydrates and 35 to 50% of plant fibers; preferably the carbohydrate content is less than 10%, advantageously less than 5%; this composition may be used as a substitute for wheat flour in the preparation of foods such as pasta, bread, bread sticks, bakery products and pastries and constitutes the basis of a method for improving the appearance of a person by achieving a loss of weight which is beneficial from the aesthetic point of view.Type: ApplicationFiled: October 18, 2001Publication date: July 25, 2002Inventor: Mathias C. Zohoungbogbo
-
Publication number: 20020090390Abstract: Provided herein is a novel and useful device and method for locally delivering and controllably releasing oxybutynin in the cervical region of a female. A device of the invention comprises a ring comprising trifluoropropylmethyl/dimethyl siloxane elastomer. A pharmaceutical composition comprising oxybutynin and an excipient is placed within a bore located in the ring, wherein the bore runs from the surface of the ring into the ring. The ring has a sufficient size such that it can be inserted into the vaginal canal of a female. A cap comprising is placed over the bore at the surface of the ring in order to contain the pharmaceutical composition within the bore. When the ring is inserted into the vaginal canal, the trifluoropropylmethyl/dimethyl siloxane elastomer controllably releases and locally delivers a therapeutically effective amount of oxybutynin to the detrusor muscle to treat the female's urinary incontinence.Type: ApplicationFiled: March 13, 2002Publication date: July 11, 2002Inventors: Anu Mahashabde, Martha Francine Kay, Donald F. Koelmel
-
Publication number: 20020037895Abstract: Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.Type: ApplicationFiled: August 13, 2001Publication date: March 28, 2002Inventors: Rolf Baenteli, Wilfried Bauer, Sylvain Cottens, Claus Ehrhardt, Ulrich Hommel, Joerg Kallen, Josef Gottfried Meingassner, Francois Nuninger, Gabriele Weitz Schmidt
-
Patent number: 6350781Abstract: A preparation suitable for sustained and extended corneal analgesia and for repeated administration consisting of subanesthetic concentrations of lidocaine. A method for corneal analgesia by administering to a patient an ophthalmic analgesic solution containing lidocaine in subanesthetic 0.4% concentration.Type: GrantFiled: August 25, 2000Date of Patent: February 26, 2002Inventor: Lee Shahinia, Jr.
-
Patent number: 6342523Abstract: Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have the formula: where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.Type: GrantFiled: December 1, 1999Date of Patent: January 29, 2002Assignee: Centaur Pharmaceuticals, Inc.Inventors: L. David Waterbury, Allan L. Wilcox, John M. Carney, Farah Mavandadi, Albert Danielzadeh
-
Patent number: 6294582Abstract: Substantially optically pure S-oxybutynin, or a pharmaceutically acceptable salt thereof, is administered as a treatment for asthma. Such treatment is provided while reducing the adverse effects associated with the administration of racemic oxybutynin.Type: GrantFiled: May 17, 2000Date of Patent: September 25, 2001Assignee: Sepracor Inc.Inventor: Thomas P. Jerussi
-
Patent number: 6274570Abstract: A liquid pesticidal composition, which is substantially free of water, comprising a hydrophobic pesticide or mixture of pesticides dissolved in an organic solvent and comprising as surfactants (a) a castor oil ethoxylate having 30-50 mol ethoxylate, (b) a branched C8-C18 alcohol ethoxylate having 5-10 mol ethoxylate, and (c) a tristyrenephenol-ethoxylate having 8-30 mol ethoxylate, or its phosphate or salt thereof. The compositions also include gels having a viscosity of 500 to 20,000 mPas and comprising additionally a gelling agent.Type: GrantFiled: December 22, 1998Date of Patent: August 14, 2001Assignee: Syngenta Crop Protection, Inc.Inventors: Manfred Vogt, William Baettig
-
Patent number: 6218428Abstract: The current invention is an ophthalmic composition that combines multiple agents necessary to perform a routine eye examination. Preferably, the composition is a mixture of a topical local anesthetic, a pupillary dilating agent, and a dye, all in solution. The composition may also include a preservative, a wetting agent, a diluting agent, and/or a buffer. The preferred composition provides a means to: 1) anesthetize the cornea to allow for pain relief, manipulation and the measurement of intraocular pressure, 2) dye the cornea and conjunctiva to allow for the detection of pathology and for the measurement of intraocular pressure, and 3) dilate the pupil to allow for examination of the optic nerve, macula, retina, retinal vasculature, and peripheral fundus.Type: GrantFiled: April 28, 2000Date of Patent: April 17, 2001Inventor: Emil Chynn
-
Patent number: 6207708Abstract: The current invention discloses hydroxyamidino derivatives useful as nitric oxide synthase inhibitors.Type: GrantFiled: March 11, 1998Date of Patent: March 27, 2001Assignee: G. D. Searle & CompanyInventors: Rolando E. Gapud, Timothy J. Hagen, E. Ann Hallinan, Donald W. Hansen, Jr., Barnett S. Pitzele, Suzanne S. Metz, R. Keith Webber, Foe S. Tjoeng, Robert E. Manning, Mihaly V. Toth
-
Patent number: 6153647Abstract: A method for treating medical patients suffering from cardiac trauma by co-administering pyruvate with a .beta.-adrenergic agonist. This method for treating cardiac trauma, such as ischemic reperfusion injury and heart failure, augments the inotropic effects of .beta.-adrenergic agents. Typical .beta.-adrenergic agonists are epinephrine, norepinephrine, dobutamine, and isoproterenol. The amount of .beta.-adrenergic agonist necessary to achieve a 50 percent increase of cardiac power is diminished five-fold when co-administered with pyruvate. Since high concentrations of agonists have many detrimental and hazardous side effects in patients, this invention would have important applications in the treatment of patients with cardiac trauma such as ischemia reperfusion injury.Type: GrantFiled: November 12, 1998Date of Patent: November 28, 2000Assignee: My-Tech, Inc.Inventors: Robert T. Mallet, James L. Caffrey, Maria Isabel Tejero-Taldo
-
Patent number: 6136804Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 12, 1999Date of Patent: October 24, 2000Assignee: Merck & Co., Inc.Inventor: Steven A. Nichtberger
-
Patent number: 6114382Abstract: The present invention provides novel compositions and methods relating to the treatment of Inflammatory Bowel Disease ("IBD"), most notably, Ulcerative Colitis, Crohn's Disease, Colitis and Diverticulitis. The invention relates to the discovery of a parasitic microsporidia infecting the epithelium cells lining the gastrointestinal tract of patients suffering from IBD. The discovery of this correlation between the disease and the microsporidia, described herein, led to the development of methods for the accurate diagnosis of patients suffering from IBD, and also of methods for treating such a patient in accordance with the invention. This discovery also provides for the development of animal models to further elucidate the mechanism of the disease and potential additional cures therefor.Type: GrantFiled: November 11, 1998Date of Patent: September 5, 2000Inventor: Itagiba G. Moretti
-
Patent number: 6060454Abstract: Methods are provided for conducting surgical procedures in a patient wherein, during the surgical procedure, autonomous ventricular electrical conductivity and escape beats are reversibly and transiently suppressed to facilitate the surgical procedure. Also provided are compositions which are capable of inducing ventricular asystole in a patient. The compositions may include an AV node blocker. In one embodiment, compositions including an atrioventricular (AV) node blocker and a .beta.-blocker are provided, wherein the .beta.-blocker is present in an amount sufficient to substantially reduce the amount of AV node blocker required to induce ventricular asystole in the patient. The compositions and methods may be used for inducing temporary ventricular asystole in a beating heart, and to facilitate the performance of a variety of surgical techniques, including minimally invasive microsurgical techniques.Type: GrantFiled: August 7, 1998Date of Patent: May 9, 2000Assignee: Duke UniversityInventor: Francis G. Duhaylongsod